FindTrial
Sign In

Single center, single-arm, Retrospective study on neoadjuvant Tx of HR LPC with apalutamide

Single center, single-arm, Retrospective study on neoadjuvant Tx of HR LPC with apalutamide

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121368
Enrollment
Unknown
Registered
2026-03-30
Start date
2026-03-30
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Apalutamide neoadjuvant group:None

Sponsors

THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients with high-risk localized prostate cancer (Gleason score > 7, or PSA > 20 ng/mL, or cT2) or locally advanced prostate cancer (cT3–4 or cN1). 2. Received apalutamide in combination with androgen deprivation therapy (ADT) as neoadjuvant treatment for 3–6 months, followed by radical prostatectomy (RP). 3. ECOG performance status of 0–1.

Exclusion criteria

Exclusion criteria: Distant metastasis (M1) detected by conventional imaging at the time of diagnosis.

Design outcomes

Primary

MeasureTime frame
Pathologic Complete Response Rate, pCR;—

Secondary

MeasureTime frame
Residual Cancer Burden (RCB);—

Countries

China

Contacts

Public ContactZhang Gejun

THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY

13897909605@163.com+86 138 9790 9605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026